#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hereditary neuropathic amyloidosis Systemic sclerosis pulmonary Ovarian cancer stage III IgA nephropathy Dupuytren's contracture Systemic mastocytosis Oesophageal adenocarcinoma Anti-glomerular basement membrane disease Mucopolysaccharidosis II Alveolar rhabdomyosarcoma Adrenocortical carcinoma Pulmonary sarcoidosis Cytokine release syndrome Waldenstrom's macroglobulinaemia Narcolepsy More trials…

    Learn about Rare Diseases

    Bronchopulmonary dysplasia – Treatment Congenital nephrogenic diabetes insipidus – Life with Disease Alagille syndrome – Basic Information Leiomyosarcoma recurrent – Diagnostics Ornithine transcarbamoylase deficiency – Life with Disease Paroxysmal nocturnal haemoglobinuria – Trials in Disease Retinoblastoma – Basic Information Chronic granulomatous disease – Treatment SAPHO syndrome – Basic Information Rhabdomyosarcoma More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Rusfertide Ecoo75 Cefalexin Doxycycline Solrikitug KETOROLAC TROMETAMOL Tadekinig Alfa Sirolimus Cpft Trifluoroacetate Catequentinib Dihydrochloride Imipramine Hydrochloride Cilgavimab Dried Ferrous Sulfate Tinzaparin Sodium Maraviroc Jab-21822 Fenofibrate Micronised GVV858 Lapatinib NALOXEGOL More therapies…

    Learn about Your Condition

    Pleural mesothelioma malignant Hepatobiliary cancer Hereditary optic atrophy Rectal cancer Pancreatic carcinoma Death neonatal Breast proliferative changes Pancreatic carcinoma stage IV Angiosarcoma recurrent Arrhythmia Glycogen storage disorder Procedural haemorrhage Migraine Dermatomyositis Idiopathic pulmonary fibrosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Crohn’s disease

  • Study of mirikizumab and tirzepatide for adults with moderate to severe Crohn’s disease who are overweight or obese

    Recruiting

    3 1
    Investigated Drugs:
    • Mirikizumab
    • Tirzepatide
    Austria Belgium Bulgaria Czechia Denmark France +9

  • Study of ly4395089 and mirikizumab in adults with moderately to severely active Crohn’s disease

    Recruiting

    2 1 1
    Investigated Diseases:
    • Colitis
    • Colitis ulcerative
    • Crohn’s disease
    Investigated Drugs:
    • Mirikizumab
    Belgium Germany Hungary Italy Poland

  • Study of mirikizumab versus azathioprine in newly diagnosed moderate-to-severe Crohn’s disease patients

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Azathioprine
    • Mirikizumab
    Germany

  • A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Guselkumab
    • Risankizumab
    Austria Belgium Czechia Denmark France Germany +7

  • A study of mirikizumab levels in breast milk of breastfeeding women with ulcerative colitis or Crohn’s disease

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colitis ulcerative
    • Crohn’s disease
    Investigated Drugs:
    • Mirikizumab
    Denmark Germany Italy Poland Spain

  • One-Year Effectiveness Study of Guselkumab in Adults with Crohn’s Disease

    Recruiting

    3 1 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Guselkumab
    France
1 2 3 … 16
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!